RA0078

antibody from Oursmab

Targeting: CD22 SIGLEC-2, SIGLEC2

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0078

Provider

Oursmab

Product name

Pinatuzumab (Biosimilar Reference Antibody) (CD22)

Antibody type

Monoclonal

Description

Pinatuzumab vedotin (also known as DCDT2980S or RG7596) is an antibody-drug conjugate (ADC). It consists of a monoclonal antibody linked to a potent cytotoxic drug. The antibody component is designed to target CD22, a cell surface receptor, and is conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). It was primarily investigated in clinical trials for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (NHL), such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Pinatuzumab (Biosimilar Reference Antibody) (CD22)-RA0078-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Pinatuzumab (Biosimilar Reference Antibody) (CD22)-RA0078 in a linear range of 15.63¨C125 ng/mL.